Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1992 Aug 15;286(Pt 1):79–84. doi: 10.1042/bj2860079

Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

J M Edelberg 1, S V Pizzo 1
PMCID: PMC1133020  PMID: 1381585

Abstract

Plasmin inhibition by alpha 2-antiplasmin (alpha 2AP) is regulated by the vascular components fibrin(ogen) fragments, plasminogen and lipoprotein (a). Kinetic analysis demonstrates that CNBr-derived fibrinogen fragments completely protect plasmin from alpha 2AP. Plasminogen and 6-aminohexanoic acid decrease the rate of inhibition by 5- and 10-fold respectively. These studies show that CNBr-derived fibrinogen fragments and 6-aminohexanoic acid bind plasmin kringle(s) with binding constants of 2 micrograms/ml and 120 microM respectively, and that plasminogen binds to alpha 2AP with an affinity of 0.5 nM. The unmodulated inhibition is not effected by the presence of lipoprotein (a), but in the presence of protective CNBr-derived fibrinogen fragments the rate of inhibition is increased by the presence of the lipoprotein. The kinetics demonstrate that lipoprotein (a) binds to CNBr-derived fibrinogen fragments with an affinity of 4 nM, displacing plasmin from the protective surface. In addition, tissue-type plasminogen activator and trypsin inhibition by alpha 2AP is not slowed by the presence of CNBr-derived fibrinogen fragments or plasminogen (Pg), respectively. These kinetics suggest that the initial reversible interaction between plasmin and alpha 2AP is mediated by binding of the inhibitor to the kringle 1 domain of plasmin, with a reversible inhibition constant (Ki) of 5.0 x 10(-10) M. Under conditions where this kringle-inhibitor interaction is blocked, the reversible inhibition still occurs between the plasmin and alpha 2AP, but the initial Ki is increased to 5.0 x 10(-9) M. These data suggest that, in the circulation, plasmin inhibition by alpha 2AP may be down-regulated by fibrin, fibrin(ogen) fragments and Pg, but up-regulated by lipoprotein (a) in the presence of fibrin or fibrin(ogen) fragments. The lipoprotein (a)-mediated promotion of plasmin inhibition may provide an additional mechanism by which the lipoprotein impairs fibrinolysis and promotes atherosclerosis.

Full text

PDF
79

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anonick P. K., Gonias S. L. Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin. Biochem J. 1991 Apr 1;275(Pt 1):53–59. doi: 10.1042/bj2750053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bachmann F., Kruithof I. E. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost. 1984 Jan;10(1):6–17. doi: 10.1055/s-2007-1004403. [DOI] [PubMed] [Google Scholar]
  3. Brockway W. J., Castellino F. J. Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Arch Biochem Biophys. 1972 Jul;151(1):194–199. doi: 10.1016/0003-9861(72)90488-2. [DOI] [PubMed] [Google Scholar]
  4. Chase T., Jr, Shaw E. p-Nitrophenyl-p'-guanidinobenzoate HCl: a new active site titrant for trypsin. Biochem Biophys Res Commun. 1967 Nov 30;29(4):508–514. doi: 10.1016/0006-291x(67)90513-x. [DOI] [PubMed] [Google Scholar]
  5. Christensen U., Clemmensen I. Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma. Biochem J. 1978 Nov 1;175(2):635–641. doi: 10.1042/bj1750635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clemmensen I., Thorsen S., Müllertz S., Petersen L. C. Properties of three different molecular forms of the alpha 2 plasmin inhibitor. Eur J Biochem. 1981 Nov;120(1):105–112. doi: 10.1111/j.1432-1033.1981.tb05675.x. [DOI] [PubMed] [Google Scholar]
  7. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  8. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  9. Eaton D. L., Fless G. M., Kohr W. J., McLean J. W., Xu Q. T., Miller C. G., Lawn R. M., Scanu A. M. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A. 1987 May;84(10):3224–3228. doi: 10.1073/pnas.84.10.3224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Edelberg J. M., Gonzalez-Gronow M., Pizzo S. V. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res. 1990 Jan 1;57(1):155–162. doi: 10.1016/0049-3848(90)90203-o. [DOI] [PubMed] [Google Scholar]
  11. Edelberg J. M., Pizzo S. V. Appendices. Kinetic models for the analysis of modulation and suppression of irreversible enzymatic inhibition. J Biol Chem. 1991 Apr 25;266(12):7494–7495. [PubMed] [Google Scholar]
  12. Edelberg J. M., Pizzo S. V. Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. Biochemistry. 1990 Jun 26;29(25):5906–5911. doi: 10.1021/bi00477a004. [DOI] [PubMed] [Google Scholar]
  13. Gonzalez-Gronow M., Edelberg J. M., Pizzo S. V. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry. 1989 Mar 21;28(6):2374–2377. doi: 10.1021/bi00432a005. [DOI] [PubMed] [Google Scholar]
  14. Gonzalez-Gronow M., Robbins K. C. In vitro biosynthesis of plasminogen in a cell-free system directed by mRNA fractions isolated from monkey liver. Biochemistry. 1984 Jan 17;23(2):190–196. doi: 10.1021/bi00297a003. [DOI] [PubMed] [Google Scholar]
  15. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  16. Hamsten A., de Faire U., Walldius G., Dahlén G., Szamosi A., Landou C., Blombäck M., Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987 Jul 4;2(8549):3–9. doi: 10.1016/s0140-6736(87)93050-9. [DOI] [PubMed] [Google Scholar]
  17. Harpel P. C., Chang T. S., Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem. 1985 Apr 10;260(7):4432–4440. [PubMed] [Google Scholar]
  18. Harpel P. C., Gordon B. R., Parker T. S. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989 May;86(10):3847–3851. doi: 10.1073/pnas.86.10.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hoff H. F., Beck G. J., Skibinski C. I., Jürgens G., O'Neil J., Kramer J., Lytle B. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988 Jun;77(6):1238–1244. doi: 10.1161/01.cir.77.6.1238. [DOI] [PubMed] [Google Scholar]
  20. Hortin G. L., Trimpe B. L., Fok K. F. Plasmin's peptide-binding specificity: characterization of ligand sites in alpha 2-antiplasmin. Thromb Res. 1989 Jun 15;54(6):621–632. doi: 10.1016/0049-3848(89)90128-x. [DOI] [PubMed] [Google Scholar]
  21. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  22. Korninger C., Collen D. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemost. 1981 Oct;46(3):662–665. [PubMed] [Google Scholar]
  23. Longstaff C., Gaffney P. J. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry. 1991 Jan 29;30(4):979–986. doi: 10.1021/bi00218a014. [DOI] [PubMed] [Google Scholar]
  24. Loscalzo J., Weinfeld M., Fless G. M., Scanu A. M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990 Mar-Apr;10(2):240–245. doi: 10.1161/01.atv.10.2.240. [DOI] [PubMed] [Google Scholar]
  25. Markus G., DePasquale J. L., Wissler F. C. Quantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen. J Biol Chem. 1978 Feb 10;253(3):727–732. [PubMed] [Google Scholar]
  26. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  27. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  28. Nieuwenhuizen W., Verheijen J. H., Vermond A., Chang G. T. Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. Biochim Biophys Acta. 1983 Feb 22;755(3):531–533. doi: 10.1016/0304-4165(83)90261-1. [DOI] [PubMed] [Google Scholar]
  29. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta. 1982 Jun 24;704(3):461–469. doi: 10.1016/0167-4838(82)90068-1. [DOI] [PubMed] [Google Scholar]
  30. Stack S., Gonzalez-Gronow M., Pizzo S. V. Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry. 1990 May 22;29(20):4966–4970. doi: 10.1021/bi00472a029. [DOI] [PubMed] [Google Scholar]
  31. Sugiyama N., Sasaki T., Iwamoto M., Abiko Y. Binding site of alpha 2-plasmin inhibitor to plasminogen. Biochim Biophys Acta. 1988 Jan 4;952(1):1–7. doi: 10.1016/0167-4838(88)90094-5. [DOI] [PubMed] [Google Scholar]
  32. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  33. Verheijen J. H., Caspers M. P., Chang G. T., de Munk G. A., Pouwels P. H., Enger-Valk B. E. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J. 1986 Dec 20;5(13):3525–3530. doi: 10.1002/j.1460-2075.1986.tb04678.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wiman B., Boman L., Collen D. On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin. Eur J Biochem. 1978 Jun 1;87(1):143–146. doi: 10.1111/j.1432-1033.1978.tb12360.x. [DOI] [PubMed] [Google Scholar]
  35. Wiman B., Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978 Mar 15;84(2):573–578. doi: 10.1111/j.1432-1033.1978.tb12200.x. [DOI] [PubMed] [Google Scholar]
  36. Wiman B., Lijnen H. R., Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta. 1979 Jul 25;579(1):142–154. doi: 10.1016/0005-2795(79)90094-1. [DOI] [PubMed] [Google Scholar]
  37. de Serrano V. S., Urano T., Gaffney P. J., Castellino F. J. Influence of various structural domains of fibrinogen and fibrin on the potentiation of plasminogen activation by recombinant tissue plasminogen activator. J Protein Chem. 1989 Feb;8(1):61–77. doi: 10.1007/BF01025079. [DOI] [PubMed] [Google Scholar]
  38. van Zonneveld A. J., Veerman H., Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4670–4674. doi: 10.1073/pnas.83.13.4670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. van Zonneveld A. J., Veerman H., Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem. 1986 Oct 25;261(30):14214–14218. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES